title: Topographical, morphological and immunohistochemical characteristics of carcinoma in situ of the breast involving sclerosing adenosis. Two distinct topographical patterns and histological types of carcinoma in situ.
abstract: OBJECTIVE
  To examine the histopathological features of 24 surgically resected carcinoma in situ (CIS) involving sclerosing adenosis (SA), with special reference to the topographical relationship between CIS and SA.
  
  
  RESULTS
  In 13 (54%) lesions, CIS was entirely surrounded by SA (type A) and in 11 (46%), CIS involved SA at least focally but was not confined to the SA area (type B). The mean size of CIS in type B (30.45 mm) was significantly larger than in type A (18.00 mm). The mean size of SA in type A (39.46 mm) was significantly larger than in type B (19.54 mm). Most type A CIS were non-high-grade, and the oestrogen receptor (ER)(+)/progesterone receptor (PgR)(+)/HER2(-) immunophenotype predominated. Most type B CIS were high-grade and six (54%) were ER(-)/PgR(-). Most type A were bcl-2(+)/p53(-) in both SA and CIS areas, but two (18%) apocrine ductal CIS of type B were bcl-2(-)/p53(+) in both SA and CIS areas. Expression of ER and cyclin D1 in SA was not different from that of SA unassociated with cancer.
  
  
  CONCLUSIONS
  Most CIS involving SA arises within SA and high-grade DCIS tends to grow beyond SA. Occasional CIS may arise outside SA and secondarily involve SA.
authors.affiliation: Department of Advanced Diagnosis, Division of Pathology, Nagoya Medical Center, Aichi, Japan. MoritaniS@aol.com
authors.forename: Suzuko
authors.initials: S
authors.lastname: Moritani
authors.forename: Shu
authors.initials: S
authors.lastname: Ichihara
authors.forename: Masaki
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Tokiko
authors.initials: T
authors.lastname: Endo
authors.forename: Mikinao
authors.initials: M
authors.lastname: Oiwa
authors.forename: Misaki
authors.initials: M
authors.lastname: Shiraiwa
authors.forename: Chikako
authors.initials: C
authors.lastname: Nishida
authors.forename: Takako
authors.initials: T
authors.lastname: Morita
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Sato
authors.forename: Takako
authors.initials: T
authors.lastname: Hayashi
authors.forename: Aya
authors.initials: A
authors.lastname: Kato
authors.forename: Hideaki
authors.initials: H
authors.lastname: Aoyama
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Yoshikawa
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology*; D002135:Calcium-Binding Proteins / Q000378:metabolism; D002278:Carcinoma in Situ / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000453:epidemiology / Q000378:metabolism* / Q000473:pathology*; D015897:Comorbidity; D019938:Cyclin D1 / Q000378:metabolism; D005260:Female; D005348:Fibrocystic Breast Disease / Q000453:epidemiology / Q000473:pathology*; D006801:Humans; D008565:Membrane Proteins / Q000378:metabolism; D008840:Microfilament Proteins / Q000378:metabolism; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012189:Retrospective Studies; D012598:Sclerosis; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D000096985:Calponins
chemical_list: D002135:Calcium-Binding Proteins; D019938:Cyclin D1; D008565:Membrane Proteins; D008840:Microfilament Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; D000096985:Calponins; C081876:CKAP4 protein, human; C508053:ERBB2 protein, human